UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...

If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

Innovations breaking barriers to children’s immunisation in Nigeria and Ethiopia win major funding from Save the Children ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

ShareThe year 2024 etched an indelible mark on Nigeria’s economic history as over 20 highprofile multinational corporations, including Unilever Nigeria Plc, Procter & Gamble, GlaxoSmithKline Consumer ...

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...